Due to these in‐vivo studies showing that DPP4/CD26 inhibition can either deter or facilitate tumor progression, we previously conducted a multi‐institutional retrospective study involving patients with advanced airway and colorectal cancers (CRCs) who were being treated for diabetes with DPP4 inhibitors. This evidence concerns the gene DPP4 and neoplasm.